In addition, Bruzzese et al. reported, in a small cohort of four patients, that the pre-emptive use of sorafenib followed by DLI in MRD-positive FLT3-ITD AML patients achieved MRD negativity in 3 patients (75%) (99). Here, FLT3 is linked to acute myeloid leukemia.